Chelsea Poe
Family · Asheboro, NCNPI 1538628656
Payments from drug & device makers
Across 111 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$526
- Lilly USA, LLC$216
- AstraZeneca$214
- Novo Nordisk$182
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$72
- Harmony Biosciences LLC$69
- plus $604 from 17 others
What the payments were for
- Food & beverage$1,883100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $526 |
| Lilly USA, LLC | 11 | $216 |
| AstraZeneca | 11 | $214 |
| Novo Nordisk | 10 | $182 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| Harmony Biosciences LLC | 4 | $69 |
| GSK | 4 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $59 |
| Amgen | 4 | $54 |
| Bayer | 3 | $54 |
| Dexcom, Inc. | 2 | $50 |
| Medtronic | 1 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Pfizer | 2 | $32 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Merck | 2 | $29 |
| Irhythm Technologies, Inc. | 2 | $29 |
| Organon | 2 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$1,883 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $67,003 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $45,118 |
| TrulicityDulaglutide | 29 | $30,103 |
| FarxigaDapagliflozin Propanediol | 14 | $23,396 |
| JardianceEmpagliflozin | 31 | $23,134 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $21,537 |
| MounjaroTirzepatide | 19 | $19,797 |
| JanuviaSitagliptin Phosphate | 22 | $15,843 |
| EliquisApixaban | 18 | $13,095 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,625 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $7,895 |
| BelsomraSuvorexant | 14 | $6,249 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,977 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,381 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $182 | $67,00369 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $61 | $53,68185 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $216 | $49,90048 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $214 | $36,26846 claims |
| Boehringer IngelheimJardiance | $15 | $23,13431 claims |
| MerckJanuvia, Belsomra | $29 | $22,09236 claims |
| PfizerEliquis | $32 | $13,09518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.
Other family in Asheboro
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.